Daily Morning Note – 20 July 2020


Stocks looked set for a mixed start to the week ahead of a ramp up in the earnings season. The euro fluctuated as EU leaders failed to reach an agreement on a recovery package over the weekend.

Futures dipped in Japan, and were little changed in Hong Kong and Australia. S&P 500 futures were steady after the gauge ended Friday higher to round out a third week of gains. Talks continued on a European stimulus deal after leaders of Germany and France walked out of a meeting with Dutch Prime Minister Mark Rutte following a dispute over details of the proposal. Oil slipped.


THE Securities Investors Association (Singapore), or Sias, does not support any potential rescue deals for Hyflux that lack a “concrete proposal” to resolve the debts due to holders of the embattled firm’s perpetual and preference shares (PnPs). In a press statement on Sunday, Sias chief David Gerald flagged that potential new white knights for Hyflux that have surfaced in the past few weeks have not made any offers yet for PnP holders.

THOMSON Medical expects to post a net loss for for the six months, as well as for the 18 months ended June 2020, due to a non-cash impairment loss in Malaysia and weaker contributions from certain segments, the mainboard-listed firm said in a profit guidance on Friday. The impairment loss arose from a significant decline in the market valuation of Thomson Medical’s 9.23ha freehold land within the Iskandar Development Region in Johor Bahru, Malaysia. This was due to political uncertainty in Malaysia and the weak property market amid the Covid-19 pandemic.

THE long stop date for Lippo Malls Indonesia Retail Trust (LMIRT)’s planned divestment of Pejaten Village and Binjai Supermall has been extended to July 23 after discussions with the parties involved, LMIRT’s manager announced in a Saturday bourse filing. In December last year, LMIRT Management entered conditional agreements to divest Pejaten Village in South Jakarta and Binjai Supermall in North Sumatra for 1.28 trillion rupiah (S$1.2 million). The buyer is NWP Retail, a joint venture between Warburg Pincus and PT City Retail Developments.

COVID-19 test kit maker Biolidics said late on Thursday that it anticipates it will take up to nine months to incorporate technology it recently licensed from the Agency for Science, Technology and Research (A*Star) into a new serology test kit. It was responding to queries from the Singapore Exchange (SGX) on Wednesday on the timing and details of the Catalist-listed company’s announcement on Tuesday night.

PROPERTY developer OUE Ltd on Friday announced that it will sell US Bank Tower – known for its cameos in Hollywood movies and a sky-high outdoor glass slide – for US$430 million. The sale price is about two-thirds of the property’s US$650 million fair value as at Dec 31, 2019. The price was arrived at after taking into account, among other things, the property’s market value and the current US property market conditions amid the Covid-19 pandemic.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, PSR


Technical Analysis: Singapore Stocks – Range bound market expected

Analyst: Chua Wei Ren

– Singapore’s GDP contract 41.2% in Q2 after the lingering effect of the Circuit Breaker from late April to early June.

– The Singapore stock market resume selling after price fails to sustain the rally beyond the key resistance level.

– Major large cap stocks have seen market reverse their gains after a good stellar growth 2 weeks ago.

– Despite poor economic outlook, the stock will likely form a ranging corrective pattern towards end of Q3.

Technical Analysis: DXY & Gold update – Fed’s potential rate cut and Q.E expectation send dollar lower

Analyst: Chua Wei Ren

– The U.S market dollar index (DXY) fell for the fourth straight weeks as the COVID-19 is still the key subject to market’s weakness.

– The ongoing EU recovery fund meeting remains in deadlock and this may cause uncertainty in the Euro, which is heavily weighted in the dollar index.

– Another reason is that the US dollar may face weakness is because the traders are factoring in further rate cuts and increase QE to support the economy.

>> Read more technical reports


Hyphens Pharma International Ltd – Building channels to establish business longevity

Recommendation: Accumulate (Initiation), Last Done: S$0.420

Target Price: S$0.435, Analyst: Tay Wee Kuang

– Exclusive distributorship of Specialty Pharmaceutical products confers high margins and strong customer loyalty.

– Expansion into both online and offline retail sales channel such as Watson’s, Guardian, Lazada and RedMart will spur growth across product portfolio.

– Hyphen Pharma continues to establish its presence within the region with expansion of product portfolio through new product launches and footprint into various sales channels.

– Initiate coverage with ACCUMULATE rating and a target price of S$0.435.

Manulife US REIT – Quality that speaks for itself

Recommendation: BUY (Initiation), Last Done: US$0.705

Target Price: US$0.80, Analyst: Natalie Ong

– Favourable portfolio attributes – occupancy of 96.5%, long WALE of 5.7 years, built-in rental escalation (c.2% p.a.), low expiries (4.4%/6.4% FY20/FY21), and high tenant retention of 76% in FY19.

– Relevance and preference for a physical workplace to continue; demand for office to moderate not abate.

– Initiate coverage with a BUY and TP of US$0.78; attractive FY20e/FY21e yield of 8.8%/9.0% and 0.88x P/NAV trading close to historical low (0.8x).

Prime US REIT – Prime for resilience

Recommendation: BUY (Initiation), Last Done: US$0.765

Target Price: US$0.88, Analyst: Tan Jie Hui

– Attractive yields of 8.9% underpinned by resilient portfolio attributes.

– Long WALE with minimal lease expiry in FY20, diversified income contribution and built-in rental escalation to support the portfolio’s gross rental and distributable income.

– Initiate coverage with a BUY and a target price of US$0.88.

SG Bonds Weekly – Week of 20 July 2020

Credit Analyst: Timothy Ang

– Last week, the performance was mixed both in equities and bonds. Asian investment grade bonds enjoyed higher yield compression compared to Asian high yield bonds.

– ESR-REIT proposed a merger with Sabana REIT, for a consideration of S$777mn, financed with S$397mn equity and S$460 debt. The combined entity gearing level is expected to be 41.7%.

– Interest rates and government bond yields have stabilised as markets entered the earnings season both in the US and in Singapore.

>> Read more research reports

HK Reports – Read up on our Hong Kong reports here


Webinar Of The Week

Market Outlook: Market Outlook: SG Banking Monthly, SG Bonds Weekly and SG Strategy 3Q20 (with stock picks)

Date: 06 July 2020

For more on Market Outlook

Phillip Research in 3 minutes: #23- Yoma Strategic Holdings; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com